Paulson D F, Zinner N R, Resnick M I, Childs S J, Love T, Madsen P O
Urology. 1986 Apr;27(4):379-87. doi: 10.1016/0090-4295(86)90321-3.
The relative safety and efficacy of minocycline and cephalexin were examined in patients with acute or chronic prostatitis. The multicenter study was of single-blind, parallel-group design. Forty-two men received minocycline (200-mg initial dose followed by 100 mg twice daily) and 44, cephalexin (500 mg four times daily); each antibiotic was administered orally for four weeks. A follow-up period of patient assessment extended for an additional six weeks. Evaluable data were available for 20 minocycline-treated patients and for 24 cephalexin-treated patients. Clinical cure or improvement without recurrence was seen in 65 per cent of the patients who received minocycline and in 46 per cent of those given cephalexin. Bacteriologic cure without relapse or reinfection occurred in 45 per cent of the minocycline-treated men and in 21 per cent of the cephalexin-treated men. Serious adverse clinical experiences were not encountered in either treatment group. Although several factors, mainly the small number of patients, precluded a statistical analysis of comparative efficacy, it was evident that more patients in the minocycline-treated group had both clinical and bacteriologic cures (35%) than did those in the cephalexin-treated group (21%).
在急性或慢性前列腺炎患者中对米诺环素和头孢氨苄的相对安全性及疗效进行了研究。该多中心研究采用单盲、平行组设计。42名男性接受米诺环素治疗(初始剂量200毫克,随后每日两次,每次100毫克),44名男性接受头孢氨苄治疗(每日四次,每次500毫克);每种抗生素均口服四周。患者评估的随访期延长六周。20名接受米诺环素治疗的患者和24名接受头孢氨苄治疗的患者有可评估数据。接受米诺环素治疗的患者中65%出现临床治愈或改善且无复发,接受头孢氨苄治疗的患者中这一比例为46%。接受米诺环素治疗的男性中45%实现细菌学治愈且无复发或再感染,接受头孢氨苄治疗的男性中这一比例为21%。两个治疗组均未出现严重不良临床事件。尽管有几个因素,主要是患者数量少,妨碍了对疗效比较进行统计学分析,但显然米诺环素治疗组中实现临床和细菌学治愈的患者比例(35%)高于头孢氨苄治疗组(21%)。